北京健康(控股)有限公司
Beijing Health (Holdings) Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2389)

DISCLOSEABLE TRANSACTION
REDEMPTION OF INTEREST IN A MONEY MARKET FUND

BACKGROUND

On 21 January 2026, the Company, as a fund unit holder, submitted a redemption request (the "**Redemption**") to the fund manager of the CUAM USD Money Market Fund (Class P) (the "**Fund**"), requesting the redemption of 1,812,940.7712 fund units (the "**Units**") held by the Company in the Fund. On 22 January 2026, the Company received the redemption confirmation from the fund manager that the redemption proceeds amounted to approximately HKD20,204,000.

LISTING RULES IMPLICATIONS

As the highest applicable percentage ratio calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Redemption exceeds 5% but is less than 25%, the Redemption constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is therefore subject to the reporting and announcement requirement, but is exempt from the circular and Shareholders' approval requirements, under the Listing Rules.

BACKGROUND

The board of directors (the "**Board**") of Beijing Health (Holdings) Limited (the "**Company**") announces that on 21 January 2026, the Company, as a fund unit holder, submitted a redemption request (the "**Redemption**") to the fund manager of the CUAM USD Money Market Fund (Class P) (the "**Fund**"), requesting the redemption of 1,812,940.7712 fund units (the "**Units**") held by the Company in the Fund. On 22 January 2026, the Company received the redemption confirmation from the fund manager that the redemption proceeds amounted to approximately HKD20,204,000.

The Company subscribed HKD20,000,000 in the Fund on 5 August 2025 (the "**Subscription**"). As all of the applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Subscription are less than 5%, the Subscription does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules.

THE CONSIDERATION

The proceeds from the Redemption amounted to approximately HKD20,204,000. The actual redemption amount has been settled in cash on 22 January 2026.

INFORMATION ON THE PARTIES

The Company and the Group

The Company is an investment holding company and the Group is principally engaged in the provision of medical care, health care and geriatric care related services and products.

The Fund

The Fund is a sub-fund of China Universal International Series which is a Hong Kong domiciled umbrella structure unit trust. Its primary investment objective is to invest in short-term deposits and high quality money market investments and achieve a return in US Dollars in line with prevailing money market rates.

The Fund Manager

The Fund Manager is China Universal Asset Management (Hong Kong) Company Limited, a company incorporated in Hong Kong with limited liability, and is licensed for type 1 (Dealing in Securities), type 4 (Advising on Securities) and type 9 (Asset Management) regulated activities by the Securities and Futures Commission of Hong Kong. The Fund Manager is a wholly owned subsidiary of the Shanghai-based China Universal Asset Management Company Limited.

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, each of the Fund and the Fund Manager is an independent third party independent of the Company and its connected persons.

FINANCIAL EFFECT OF THE REDEMPTION

It is expected that the Group will record a gain on Redemption in the amount of approximately HKD204,000, which was calculated based on the difference between the redemption proceeds in the amount of HKD20,204,000 and the historical purchase cost of the Fund in the amount of HKD20,000,000. The actual amount of gain or loss as a result of the Redemption to be recorded by the Company will be subject to review and final audit by the auditors of the Company.

USE OF PROCEEDS

The proceeds from the Redemption amounted to approximately HKD20,204,000 will be used for general working capital purpose and to fund the upcoming investments of the Group in the future.

REASONS FOR THE REDEMPTION

The Company's investment in the Fund was a treasury management initiative aimed at enhancing returns on its idle funds. The Board considers the Redemption to be in the ordinary and usual course of the Group's treasury management activities, conducted on normal commercial terms. The Board is of the view that the Redemption is fair and reasonable and in the interests of the Company and its shareholders as a whole.

LISTING RULES IMPLICATIONS

As the highest applicable percentage ratio calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Redemption exceeds 5% but is less than 25%, the Redemption constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is therefore subject to the reporting and announcement requirement, but is exempt from the circular and Shareholders' approval requirements, under the Listing Rules.

DEFINITIONS

"Board"	the board of Directors
"Company"	Beijing Health (Holdings) Limited, a company incorporated in the Cayman Islands with limited liability and the shares of which are listed on the Main Board of the Stock Exchange (stock code: 2389)
"connected person(s)"	has the meaning ascribed to it in the Listing Rules
"Director(s)"	the director(s) of the Company

“Fund”	CUAM USD Money Market Fund (Class P), a sub-fund of China Universal International Series
“Group”	the Company and its subsidiaries
“HKD”	Hong Kong dollar, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Independent Third Party(ies)”	third party(ies) independent of and not connected (as defined under the Listing Rules) with the Company and its connected person(s)
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Redemption”	the redemption by the Company of all of its 1,812,940.7712 Class P fund units in the Fund
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By Order of the Board of
Beijing Health (Holdings) Limited
Zhu Shi Xing
Chairman

Hong Kong, 22 January 2026

As at the date of this announcement, the Board comprises four Executive Directors, namely Mr. Zhu Shi Xing, Mr. Liu Xue Heng, Mr. Gu Shan Chao and Mr. Wang Zheng Chun and four Independent Non-Executive Directors, namely Mr. Tse Man Kit, Keith, Mr. Wu Yong Xin, Mr. Zhang Yun Zhou and Ms. Yang Xiao Yan.